Dementia is the biggest health challenge facing the UK’s ageing population with 900,000 currently living with the disease and predicted to increase to 1.6 million by 2050. Now, for the first ...

Regular use of strong opioids may significantly increase risk for all-cause and vascular dementia plus reduced brain volume and cognitive performance.

There are currently no approved treatments in Canada that can slow the progression of Alzheimer's, only drugs to quiet ...

Vascular Dementia Treatment Market The global vascular dementia treatment market, valued at USD 4.65 billion in 2022, is projected to grow steadily to USD 5.64 billion by the end of 2023, reflecting a ...

Breast cancer survivors treated with radiation therapy have an 8% lower risk of developing Alzheimer’s disease, albeit only ...

Semaglutide — the active ingredient in type 2 diabetes and weight-loss glucagon-like peptide-1 agonist ( GLP-1) medications ...

Vascular dementia is the second most common type of dementia after Alzheimer’s disease. It happens when blood flow to the brain is reduced or blocked, usually due to strokes or damage to small blood ...

A new study involving nearly 1.7 million patients suggests that semaglutide — a drug that mimics a gut hormone to lower blood ...

What makes this tool innovative is its ability to detect subtle brain activity patterns often invisible to the human eye and ...

Sparse Data on Systemic Treatments and Psoriasis. Several international reports have linked psoriasis with dementia, including a 2019 study that found an elevated risk associated with the skin ...

Learn how to manage dementia and heart disease simultaneously. Discover medication tips, lifestyle changes, and care strategies for dual conditions.

Semaglutide- the active ingredient in 'Wegovy' and 'Ozempic'- may lower dementia risk in people with type 2 diabetes. | Drug ...